Table 2.

Incidence of all-cause end-stage renal disease among SLE patients in the Georgia Lupus Registry, through 4/30/11^a

Cohort	No. of patients at risk	No. of ESRD events	Total patient- years at risk	Median (IQR) years to ESRDb	Incidence rate, per 1000 patient-years (95% CI)	5-year cumulative incidence,c %
Incident SLE by combined case definitiond	344	29	2603.8	4.1 (2.0-5.9)	11.1 (7.7-16.0)	5.2
Incident SLE by≥4 ACR criteria only	266	25	2007.8	4.1 (1.3-5.8)	12.5 (8.4-18.4)	6.0
Point prevalent SLEe by combined case definitiond	1488	95	---	2.6 (1.6-4.6)	---	5.2

ACR, American College of Rheumatology; ESRD, end-stage renal disease; IQR, interquartile range; SLE, systemic lupus erythematosus.

^aLast date of death follow-up in the Georgia Lupus Registry. A total of 30 patients initiated ESRD treatment between date of SLE diagnosis and 9/30/12, the last date of ESRD follow-up.

^bAmong those who progress to ESRD by 4/30/11.

^cRepresenting 18, 16, and 78 ESRD events within 5 years for the three cohorts listed.

^dCombined case definition, ≥4 ACR criteria, 3 ACR criteria plus treating rheumatologist’s diagnosis, or renal involvement as indicated by biopsy consistent with class II-VI lupus nephritis or ESRD requiring dialysis or renal transplantation.

^ePoint prevalent cohort of patients in the GLR alive with an existing diagnosis of SLE (primary combined case definition) and free of ESRD on 12/31/04. Because patients who died with SLE prior to 12/31/04 were at risk for ESRD, patient-years and incidence rates were not calculated for this cohort.